Showing results (31-40 of 79) with videos related to
Sort By:
Pageof 8
Diabetologia|September 18, 2014
Impact of age, age at diagnosis and duration of diabetes on the risk of macrovascular and microvascular complications and death in type 2 diabetesSophia Zoungas, Mark Woodward, Qiang Li, et al.Diabetes Care|June 1, 2014
Do cardiac biomarkers NT-proBNP and hsTnT predict microvascular events in patients with type 2 diabetes? Results from the ADVANCE trialPaul Welsh, Mark Woodward, Graham S Hillis, et al.Journal of Neurology, Neurosurgery, and Psychiatry|May 16, 2014
Degree of blood pressure reduction and recurrent stroke: the PROGRESS trialHisatomi Arima, Craig Anderson, Teruo Omae, et al.Cerebral Circulation - Cognition and Behavior|January 6, 2025
Effect of randomised blood pressure lowering treatment and intensive glucose control on dementia and cognitive decline according to baseline cognitive function and other subpopulations of individuals with type 2 diabetes: Results from the ADVANCE trialKatie Harris, Jessica Gong, Stephen MacMahon, et al.Diabetes, Obesity & Metabolism|March 30, 2021
Sex differences in risk factors for cognitive decline and dementia, including death as a competing risk, in individuals with diabetes: Results from the ADVANCE trialJessica Gong, Katie Harris, Maree Hackett, et al.Scientific Reports|March 9, 2017
Evidence from single nucleotide polymorphism analyses of ADVANCE study demonstrates EFNB3 as a hypertension risk geneJohanne Tremblay, Yujia Wang, John Raelson, et al.Diabetes, Obesity & Metabolism|May 4, 2019
Response of 1,5-anhydroglucitol level to intensive glucose- and blood-pressure lowering interventions, and its associations with clinical outcomes in the ADVANCE trialElizabeth Selvin, Dan Wang, John William McEvoy, et al.Hypertension (Dallas, Tex. : 1979)|April 30, 2019
Effects of Blood Pressure Lowering on Clinical Outcomes According to Baseline Blood Pressure and Cardiovascular Risk in Patients With Type 2 Diabetes MellitusFaisal Rahman, John W McEvoy, Toshiaki Ohkuma, et al.Clinical Journal of the American Society of Nephrology : CJASN|July 27, 2022
Short-Term Changes in Serum Potassium and the Risk of Subsequent Vascular Events and Mortality: Results from a Randomized Controlled Trial of ACE InhibitorsToshiaki Ohkuma, Katie Harris, Mark Cooper, et al.Journal of the American Heart Association|March 31, 2026
Blood Pressure Parameters and Risk of Cognitive Decline and Dementia in Type 2 Diabetes: Results From the ADVANCE TrialSultana Shajahan, Mark Woodward, Craig S Anderson, et al.Pageof 8